Drugs that contain Osimertinib Mesylate

1. Drug name - TAGRISSO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(9 years from now)

CN105254616A ASTRAZENECA Substituted N-(2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN104109161B ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN104109151B ASTRAZENECA N - (2 - (2-Methylamino)--4 - Methoxy - -5-[4 - (1-Methyl-Indole - -3 - Yl) Pyrimidine - -2 - Yl] Amino} Phenyl) -2 - Acrylamide Mesylate Polymorph
Jul, 2032

(9 years from now)

CN103702990B ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN104109161A ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN105348266B ASTRAZENECA Substituted 3-Chloro-N - (3 - (Pyrimidin - -2 - Ylamino) Phenyl] Propanamide Or A Salt Thereof
Jul, 2032

(9 years from now)

CN105254616B ASTRAZENECA Substituted N - (2-Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105175396B ASTRAZENECA Substituted 4-Methoxy -N3-(Pyrimidin - -2 - Yl) Phenyl]--1, 3-Diamine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105198862B ASTRAZENECA Substituted N - (4-Fluoro - -2 - Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN104109151A ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN105175396A ASTRAZENECA A Substituted 4-Methoxy-N3-(Pyridine--2-Yl) Benzene-1, 3-Diamine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN105198862A ASTRAZENECA Substituted N-(4-Fluorin--2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof
Jul, 2032

(9 years from now)

CN103702990A ASTRAZENECA 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer
Jul, 2032

(9 years from now)

CN105348266A ASTRAZENECA Substituted 3-Chlorine-N-[3-(Pyridine--2-Ylamino) Phenyl] Propanamide Or Salt
Jul, 2032

(9 years from now)

IN297581B ASTRAZENECA 2 - (2, 4, 5 - Substituted -Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3686194A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP3686194B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP3686193B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP3686193A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds
Jul, 2032

(9 years from now)

EP2736895A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3009431A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3333161A1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3333161B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP3009431B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

EP2736895B1 ASTRAZENECA 2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020 ASTRAZENECA Pharmaceutical compositions comprising AZD9291 Jan, 2035

(12 years from now)

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription
EQ 80MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.